How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study

da Graça FF, Iwabe C, Nucci A, de Rezende TJR, França MC Jr.
Muscle Nerve 2026 Feb 2. doi: 10.1002/mus.70169
This study aimed to identify the most sensitive clinical, patient-reported, and neurophysiological measures to detect short-term disease progression in untreated adult SMA patients. Amongst every clinician-reported outcomes (MFM, HFMSE, RULM) and patient-reported outcomes (MFIS, CMAP, MUNIX), the MFM was the most sensitive to short-term progression and most closely aligned with neurophysiological markers, supporting its use as primary outcome in clinical trials involving adult SMA patients.

Lien PubMed

Articles dans les revues scientifiques

Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy

Trundell D, Le Scouiller S, Gorni K, Seabrook T, Vuillerot C, SMA MFM Study Group. Neurol Ther. 2020. 9(2):575-584. Étude de la validité et de la fiabilité de la MFM32 chez des personnes atteintes de maladies neuromusculaires, y compris d’amyotrophie spinale infantile...

lire plus